China’s BGI Genomics gets sued again
A U.S.-China patent war continues.
California-based genomics company Illumina filed another lawsuit last week against its Chinese rival, BGI Genomics, over alleged patent infringement, this time in Hong Kong, the South China Morning Post reported.
The U.S. biotech accuses the Shenzhen-based company’s subsidiaries of infringing on a Hong Kong patent related to Covid-19 testing. The Hong Kong government recently announced that the city is launching a universal testing plan to offer all residents one free Covid-19 test. BGI is one of three Chinese laboratories recruited to help with the city-wide, voluntary testing program.
According to a court filing, the patent, called “Modified Nucleotides for Polynucleotide Sequencing,” protects rights to a technique related to next-generation sequencing.
Illumina’s lawsuit seeks to stop BGI from conducting its testing, as well as manufacturing, stocking, supplying, selling, and using test kits that involve the patent.
Since March last year, Illumina has sued BGI on multiple occasions over patent issues in different countries. In June, a U.S. federal court issued a preliminary injunction against BGI companies that prohibits them from launching its sequencing instruments and reagents in the country.
California-based genomics company Illumina filed another lawsuit last week against its Chinese rival, BGI Genomics, over alleged patent infringement, this time in Hong Kong, the South China Morning Post reported.
The U.S. biotech accuses the Shenzhen-based company’s subsidiaries of infringing on a Hong Kong patent related to Covid-19 testing. The Hong Kong government recently announced that the city is launching a universal testing plan to offer all residents one free Covid-19 test. BGI is one of three Chinese laboratories recruited to help with the city-wide, voluntary testing program.
According to a court filing, the patent, called “Modified Nucleotides for Polynucleotide Sequencing,” protects rights to a technique related to next-generation sequencing.
Illumina’s lawsuit seeks to stop BGI from conducting its testing, as well as manufacturing, stocking, supplying, selling, and using test kits that involve the patent.
Since March last year, Illumina has sued BGI on multiple occasions over patent issues in different countries. In June, a U.S. federal court issued a preliminary injunction against BGI companies that prohibits them from launching its sequencing instruments and reagents in the country.
.png)
No hay comentarios:
Publicar un comentario